Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Imprint’s DepotOne needle achieves CE Mark

12.10.2004


Imprint Pharmaceuticals (www.imprintpharma.com) is pleased to announce that its DepotOne needle technology has received its CE Mark and is now cleared for use in Europe. This CE Approval means that the DepotOne needle can be incorporated into clinical studies and existing products with minimal additional regulatory work.



DepotOne is a ‘small’ needle which can replace large needles. It has the penetration characteristics of a small needle with the flow of a large needle. The needle delivers highly viscous materials and will eliminate the need to resort to an unacceptably large needle for subcutaneous or intramuscular injections.

DepotOne is revolutionary as it enables higher doses to be injected. A higher deliverable dose means that new therapeutic products can be developed which have substantially improved product characteristics. The technology is particularly applicable for slow release or depot injectables including pegylated compounds, polymers and highly concentrated protein formulations.


Marketers are fully aware of the significant problems posed by the use of larger needles to the reputation and marketability of an injectable therapeutic product. Thus companies are planning to use DepotOne to reduce the impact of the large needle issue so the positive aspects of their product can be highlighted.

The technology is now being used in a number of clinical trials for high value long acting injectable therapeutics. Kevin Maynard, Business Development Director of Imprint Pharmaceuticals said “DepotOne creates a sea change in the presentation of injectable therapeutics. No longer do patients need to be faced with unacceptably large needles. I believe DepotOne will play a vital role in lowering the resistance to uptake of many of the new biological therapies coming through pharmaceutical companies’ product development lines.”

Imprint Pharmaceuticals Ltd is a centre of expertise in complex injectables. The company supplies tools to enhance the delivery and manufacture of these problematic formulations. Imprint has a range of patented injection devices which enhance the delivery of formulations containing particulates, viscous materials, gels and polymers. In addition, Imprint provides consultancy and patented technologies to enable rapid formulation and scale up of manufacture. Our expertise and patented technologies extend the range of complex injectable products enabling our clients to gain a commercial edge.

Dr Kevin Maynard | alfa
Further information:
http://www.Imprintpharma.com
http://www.oxin.co.uk/

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>